--- title: "A Look At Vaxart’s (VXRT) Valuation As New Norovirus Breastfeeding Study Gains Attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/274206901.md" description: "Vaxart (VXRT) has gained attention following the publication of Phase 1 data on its oral bivalent norovirus vaccine for breastfeeding women, showing promising immune responses. Despite a recent share price surge of over 83%, its long-term returns remain weak. Analysts suggest Vaxart is undervalued at $0.64, with a fair value estimate of $4.00, indicating significant growth potential if further developed. However, risks include potential disappointments in upcoming trials and funding challenges. Investors are encouraged to explore other healthcare stocks and consider the broader market context." datetime: "2026-01-29T21:32:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274206901.md) - [en](https://longbridge.com/en/news/274206901.md) - [zh-HK](https://longbridge.com/zh-HK/news/274206901.md) --- # A Look At Vaxart’s (VXRT) Valuation As New Norovirus Breastfeeding Study Gains Attention ## Why Vaxart’s Norovirus Data Matters for Investors Vaxart (VXRT) has drawn fresh attention after npj Vaccines published Phase 1 data on its single dose, oral bivalent norovirus vaccine in postpartum, breastfeeding women, highlighting immune responses in both mothers and their infants. See our latest analysis for Vaxart. The new npj Vaccines publication comes after a strong 30 day share price return of 83.38% and 90 day share price return of 81.95%. However, the 1 year total shareholder return of 11.61% and 5 year total shareholder return of 93.50% remain weak, suggesting recent momentum is building off a much lower base. If this kind of early stage biotech progress has your attention, it could be a useful moment to scan other healthcare stocks that might fit your watchlist next. With Vaxart trading at US$0.64 after a sharp short term rebound and a long history of weak multi year returns, is the norovirus progress still underappreciated here, or is the market already pricing in future growth? ## Most Popular Narrative: 84% Undervalued With Vaxart at $0.64 and the most followed narrative pointing to a Fair Value of $4.00, the gap between price and expectations is wide. > _The second generation oral norovirus candidate, which produced stronger fecal IgA and serum responses than first generation constructs in Phase I, sits in an area with no approved vaccines and an estimated US$10 billion annual economic burden in the United States, which could have a meaningful impact on future revenue if partnered and developed further._ _Read the complete narrative._ Curious how a loss making biotech ends up with that Fair Value? The narrative focuses on shifting margins, changing revenue mix and an ambitious future earnings multiple. **Result: Fair Value of $4.00 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this bullish setup can quickly unravel if the large Phase IIb COVID 19 trial disappoints, or if fresh funding and partnerships prove slower or smaller than hoped. Find out about the key risks to this Vaxart narrative. ## Build Your Own Vaxart Narrative If the current story does not quite fit your view, or you would rather weigh the data yourself, you can frame a fresh narrative in just a few minutes with Do it your way. A great starting point for your Vaxart research is our analysis highlighting 3 important warning signs that could impact your investment decision. ## Looking for more investment ideas? If Vaxart has you thinking differently about risk and reward, do not stop here. Widen your search now or you could miss your next key idea. - Spot potential early movers by scanning these 3523 penny stocks with strong financials that pair smaller market caps with solid financial markers and clear business models. - Position yourself for long term tech shifts by checking these 24 AI penny stocks focused on companies applying artificial intelligence to real world problems. - Hunt for mispriced opportunities with these 880 undervalued stocks based on cash flows where current prices sit below cash flow based estimates. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VXRT.US](https://longbridge.com/en/quote/VXRT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md) - [Aligos expands Phase 2 B-SUPREME HBeAg- cohort for pevifoscorvir sodium HBV trial](https://longbridge.com/en/news/282738920.md) - [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md) - [J&J first-quarter profit beats on cancer drug Darzalex demand; raises 2026 outlook](https://longbridge.com/en/news/282672407.md) - [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md)